Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Novartis Procter and Gamble |
---|---|
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00127270 |
This study is designed to investigate the efficacy and safety of treatment of overactive bladder with darifenacin administered alone or in conjunction with behavioral modification therapies.
Condition | Intervention | Phase |
---|---|---|
Urinary Incontinence |
Drug: Darifenacin Behavioral: Behavioral therapy |
Phase IV |
Study Type: | Interventional |
Study Design: | Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study |
Official Title: | Using Behavioral Therapy in Combination With Drug-Darifenacin for Symptoms of Overactive Bladder |
Enrollment: | 395 |
Study Start Date: | May 2005 |
Study Completion Date: | February 2006 |
Arms | Assigned Interventions |
---|---|
1: Experimental
Darifenacin
|
Drug: Darifenacin
Darifenacin tablets 7,5 mg once daily with the possibility to up-titrate to 15 mg once daily
|
2
Darifenacin in combination with Behavioral Modification Programme for Symptoms of Overactive Bladder
|
Drug: Darifenacin
Darifenacin tablets 7,5 mg or 15 mg once daily
Behavioral: Behavioral therapy
Behavioral Modification Programme for symptoms of overactive bladder
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Study Director: | Novartis Pharmaceuticals Corp. | Novartis Pharmaceutical |
Responsible Party: | Novartis ( External Affairs ) |
Study ID Numbers: | CDAR328AUS01 |
Study First Received: | June 30, 2005 |
Last Updated: | January 23, 2008 |
ClinicalTrials.gov Identifier: | NCT00127270 |
Health Authority: | United States: Institutional Review Board |
OAB Overactive Bladder Bladder hyperactivity |
Urge Incontinence Incontinence Bladder |
Signs and Symptoms Urinary Bladder, Overactive Cystocele Darifenacin Urologic Diseases |
Urination Disorders Urinary Bladder Diseases Hyperkinesis Urinary Incontinence Urinary Incontinence, Urge |
Muscarinic Antagonists Urological Manifestations Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action |
Cholinergic Antagonists Physiological Effects of Drugs Cholinergic Agents Pharmacologic Actions |